No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults

• Main Authors: Rajinder Bhardwaj (Author), Michael S. Hanna (Author), Beth A. Morris (Author), Kyle T. Matschke (Author), Richard Bertz (Author), Robert S. Croop (Author), Jing Liu (Author)
• Format: Book
• Published: Wiley, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract A single‐center, phase I, partially double‐blind (double‐blind regarding doses of rimegepant and placebo, and open label with respect to moxifloxacin), randomized, 12‐sequence, four‐period crossover study of therapeutic (75 mg) and supratherapeutic (300 mg) doses of rimegepant with placebo...